Cargando…

Lean non-alcoholic fatty liver disease: do not forget diabetes

Detalles Bibliográficos
Autores principales:	Patoulias, Dimitrios Ioannis, Kalogirou, Maria-Styliani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191936/ https://www.ncbi.nlm.nih.gov/pubmed/32368679 http://dx.doi.org/10.5114/amsad.2019.90146

Ejemplares similares

Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2018)

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Hepatitis C virus infection and atherosclerotic cardiovascular disease: recent knowledge, further insights
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease in patients with inflammatory bowel disease might boost cardiovascular disease burden
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Meckel’s diverticulum complications in three first-degree relatives: time to rethink familial predisposition?
por: Patoulias, Ioannis, et al.
Publicado: (2020)

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Growing challenge of post-liver transplantation non-alcoholic fatty liver disease
por: Kalogirou, Maria Styliani, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease, diabetes medications and blood pressure
por: Ilias, Ioannis, et al.
Publicado: (2021)

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Serum chemerin in patients with rheumatoid arthritis: can it unravel the Chimera of concomitant type 2 diabetes?
por: Patoulias, Dimitrios Ioannis
Publicado: (2020)

Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
por: Abbas, Tahany, et al.
Publicado: (2020)

miRNA-122: Can it unravel an alternative pathway in early diagnosis and prognosis of type 2 diabetes mellitus?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Co-infection with Influenza: Do Not Forget Aspergillus in the Immunosuppressed Neutropenic Host
por: Jung, Dong Sik, et al.
Publicado: (2014)

Does a gluten-free diet determine the efficacy of sotagliflozin in patients with concomitant type 1 diabetes mellitus and celiac disease?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease in lean individuals
por: Albhaisi, Somaya, et al.
Publicado: (2019)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Sexual dysfunction among women with systemic lupus erythematosus: might it reflect cardiovascular disease burden?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Body Composition and Non-alcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2016)

Letter to the Editor: Do Not Forget to Measure Grip Strength
por: Ives, Graham C., et al.
Publicado: (2021)

Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Eyeing non-alcoholic fatty liver disease: The noninvasive way
por: Gude, Dilip
Publicado: (2011)

Silymarin: An option to treat non-alcoholic fatty liver disease
por: Colica, Carmela, et al.
Publicado: (2017)

Noninvasive Imaging for the Evaluation of Non-Alcoholic Fatty Liver Disease Spectrum
por: Liu, Qianjiao, et al.
Publicado: (2021)

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
por: Jeong, Seogsong, et al.
Publicado: (2023)

Recurrent Encephalopathy with Metabolic Acidosis and Hypoglycemia: Do not Forget Fructose Metabolism
por: Hiremath, Prabhudev M., et al.
Publicado: (2022)

Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications
por: Kumar, Ramesh, et al.
Publicado: (2017)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population
por: Li, Min-ran, et al.
Publicado: (2023)

Intracranial hemorrhage and COVID-19, but please do not forget “old diseases” and elective surgery
por: Montemurro, Nicola
Publicado: (2021)

Multipronged Approach to Assess Risk Factors for Non-alcoholic Fatty Liver Disease
por: Hidrus, Aizuddin, et al.
Publicado: (2022)

Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Don’t forget the bladder!
por: Oosterveld, Bernard J., et al.
Publicado: (2018)

Don’t Forget Dengue!
por: Nyamugunduru, G
Publicado: (1998)

Comments on Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran
por: Karimi-Sari, H., et al.
Publicado: (2017)

Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease
por: Liu, Dong, et al.
Publicado: (2022)

Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome
por: Boonchai, Punyisa, et al.
Publicado: (2022)

Are we forgetting non-COVID-19-related diseases during lockdown?
por: Tartara, Fulvio, et al.
Publicado: (2020)

COVID-19 - Opportunity for online education: Do not forget the ethical considerations in teaching learners
por: Fakari, Fahimeh Rashidi, et al.
Publicado: (2021)

Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study
por: Wang, Wenting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ddv70qudqaj0nl6q8g4pjmgfml